Congenital CYtoMEgalovirus Infection in VIEtnam (CYMEVIE)

Congenital Cytomegalovirus Infection in Vietnam: Prevalence, Morbidity and Risk Factors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04822142

Acronym

CYMEVIE

Enrollment

5000

Registered

2021-03-30

Start date

2022-04-01

Completion date

2026-06-01

Last updated

2024-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Infection, Neonatal Disease, Prenatal Infection

Keywords

CYMEVIE, Cytomegalovirus, Congenital Cytomegalovirus infection, CMV PCR, CMV, cCMV

Brief summary

To estimate the prevalence of congenital CMV infection in Vietnamese neonates and relating morbidity within 2-year follow-up. Along with evaluating the predictive value of the presence and the level of CMV replication in the first trimester in a highly seropositive population

Detailed description

Congenital cytomegalovirus infection (cCMV) is the main non-genetic cause of sensorineural hearing loss (SNHL), and a major cause of neuro-disability. High maternal CMV prevalence seems to be consistently associated with high prevalence of cCMV infection but the associated morbidity might be different from one population to another. There exists no serologic marker useful to differentiate non-primary infection from primary infection. Since the morbidity of cCMV is similar between both primary and non-primary maternal infection, and to be infected in the first trimester is the major risk factor for long-term sequelae in neonates. Hence, it is needed to focus on finding markers that predict cCMV after maternal infection in the first trimester of pregnancy. To date, the epidemiology of cCMV, the morbidity related to cCMV in Vietnamese population and the predictive value of Cytomegalovirus Polymerase Chain Reaction (CMV PCR) in maternal blood and urine in the first trimester remain unknown. Therefore, it is necessary to conduct this study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Vietnamese pregnant women in the first trimester of pregnancy and at delivery and subsequent live neonates at birth. * Informed consent

Exclusion criteria

* Women under 18 years old. * Miscarriages * Stillbirths * Premature delivery before 34th gestational week * Loss to follow-up maternal monitoring. * Participation in another interventional study that influences management of labour at delivery or perinatal morbidity or mortality.

Design outcomes

Primary

Measure	Time frame	Description
Proportion of congenital CMV infection in Vietnamese neonates	Within 7 days from birth	Number of CMV positive neonates among all tested neonates

Secondary

Measure	Time frame	Description
To estimate the prevalence of cCMV related hearing loss in neonates	Up to 25 months from recruitment	Proportion of cCMV related hearing loss in neonates in all cCMV neonates
To estimate the prevalence of cCMV related neurological sequelae in neonates	Up to 25 months from recruitment	Proportion of cCMV related neurological sequelae in neonates in all cCMV neonates
To estimate CMV seroprevalence in pregnant Vietnamese women	Up to 25 months from recruitment	Proportion of seropositive women in all tested pregnant women, including mother of CMV positive neonates and control group
To evaluate the value of a positive CMV PCR in maternal whole blood in the first trimester to predict infection in the neonates	Up to 25 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal whole blood in the first trimester between women who gave birth to an infected neonate and women gave birth to an uninfected neonate from control group
To evaluate the value of a positive CMV PCR in maternal urine in the first trimester to predict infection in the neonates	Up to 25 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal urine in the first trimester between women who gave birth to an infected neonate and women gave birth to an uninfected neonate from control group
To evaluate the value of a positive CMV PCR in maternal saliva in the first trimester to predict cCMV infection in the neonates	Up to 25 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal saliva in the first trimester between women who gave birth to an infected neonate and women gave birth to an uninfected neonate from control group
To evaluate the value of a positive CMV PCR in maternal whole blood at delivery to predict infection in the neonates	Up to 25 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal whole blood at delivery between women who gave birth to an infected neonate and women gave birth to an uninfected neonate from control group
To evaluate the value of a positive CMV PCR in maternal urine at delivery to predict infection in the neonates	Up to 25 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal urine at delivery between women who gave birth to an infected neonate and women gave birth to an uninfected neonate from control group
To evaluate the value of a positive CMV PCR in whole blood in the first trimester to predict the presence of symptomatic cCMV infection in neonates	Up to 25 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal whole blood in the first trimester between symptomatic infected neonates and asymptomatic infected neonates
To evaluate the value of a positive CMV PCR in maternal urine in the first trimester to predict a cCMV symptomatic infection in neonates	Up to 25 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal urine in the first trimester between symptomatic infected neonates and asymptomatic infected neonates
To evaluate the value of a positive CMV PCR in maternal saliva in the first trimester to predict the presence of symptomatic cCMV infection in neonates	Up to 25 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal saliva in the first trimester between symptomatic infected neonates and asymptomatic infected neonates
To evaluate the value of a positive CMV PCR in maternal whole blood at delivery to predict the presence of symptomatic cCMV infection in neonates	Up to 25 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal whole blood at delivery between symptomatic infected neonates and asymptomatic infected neonates
To evaluate the value of a positive CMV PCR in maternal urine at delivery to predict a cCMV symptomatic infection in neonates	Up to 25 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal urine at delivery between symptomatic infected neonates and asymptomatic infected neonates
To evaluate the association between CMV PCR viral load in maternal whole blood at first trimester and at delivery in mothers with infected neonates	Up to 25 months from recruitment	Evaluation the change of CMV PCR viral load in maternal whole blood at first trimester and at delivery in mothers with infected neonates
To estimate the prevalence of symptomatic cCMV in neonates	Up to 25 months from recruitment	Proportion of neonates presenting with at least one symptom related to cCMV in all cCMV neonates
To evaluate the association between CMV PCR viral load in maternal whole blood at first trimester and at delivery in mothers with uninfected neonates in control group	Up to 25 months from recruitment	Evaluation the change of CMV PCR viral load in maternal whole blood at first trimester and at delivery in mothers with uninfected neonates in control group
To evaluate the association between CMV PCR viral load in maternal urine at first trimester and at delivery in mothers with uninfected neonates in control group	Up to 25 months from recruitment	Evaluation the change of CMV PCR viral load in maternal urine at first trimester and at delivery in mothers with uninfected neonates in control group
To calculate the false positive rate of CMV PCR on neonatal saliva versus on dry blood spot in screening congenital CMV infection	Up to 25 months from recruitment	Calculation of the rate of positive CMV PCR on neonatal saliva with a negative result on CMV PCR on neonatal dry blood spot in all CMV positive on neonatal saliva
To calculate the false positive rate of CMV PCR on neonatal saliva versus on urine in screening congenital CMV infection	Up to 25 months from recruitment	Calculation of the rate of positive CMV PCR on neonatal saliva with a negative result on CMV PCR on neonatal urine in all CMV positive on neonatal saliva
To evaluate risks factors for cCMV in Vietnamese women	Up to 25 months from recruitment	Factors that may differ between mothers of uninfected neonates and mothers of infected ones regarding maternal age, parity, gestity, twin pregnancy, known health conditions including hypertension, diabetes, HIV, auto immune diseases and living conditions will be analyzed
To estimate the prevalence of symptomatic cCMV at 2 years of age	Up to 48 months from recruitment	Proportion of infants presenting with at least one symptom related to cCMV at 2 years of age in all cCMV infants
To estimate the prevalence of cCMV related hearing loss at 2 years of age	Up to 48 months from recruitment	Proportion of infants with cCMV related hearing loss at 2 years of age in all cCMV infants
To estimate the prevalence of cCMV related neurological sequelae at 2 years of age	Up to 48 months from recruitment	Proportion of infants with cCMV related neurological sequelae at 2 years of age in all cCMV infants
To evaluate the value of a positive CMV PCR in maternal whole blood in the first trimester to predict the cCMV long-term sequelae at the age of 2 years	Up to 48 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal whole blood in the first trimester between infected infants with long-term sequelae at 2 years of age and infected infants without long-term sequelae at 2 years of age
To evaluate the value of a positive CMV PCR in maternal urine in the first trimester to predict the cCMV long-term sequelae at the age of 2 years	Up to 48 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal urine in the first trimester between between infected infants with long-term sequelae at 2 years of age and infected infants without long-term sequelae at 2 years of age
To evaluate the value of a positive CMV PCR in maternal saliva in the first trimester to predict the cCMV long-term sequelae at the age of 2 years	Up to 48 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal saliva in the first trimester between between infected infants with long-term sequelae at 2 years of age and infected infants without long-term sequelae at 2 years of age
To evaluate the value of a positive CMV PCR in maternal whole blood at delivery to predict the cCMV long-term sequelae at the age of 2 years	Up to 48 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal whole blood at delivery between between infected infants with long-term sequelae at 2 years of age and infected infants without long-term sequelae at 2 years of age
To evaluate the value of a positive CMV PCR in maternal urine at delivery to predict the cCMV long-term sequelae at the age of 2 years	Up to 48 months from recruitment	Comparison of the proportion of a positive CMV PCR in maternal urine at delivery between between infected infants with long-term sequelae at 2 years of age and infected infants without long-term sequelae at 2 years of age
To evaluate the association between CMV PCR viral load in maternal urine at first trimester and at delivery in mothers with infected neonates	Up to 25 months from recruitment	Evaluation the change of CMV PCR viral load in maternal urine at first trimester and at delivery in mothers with infected neonates

Countries

Vietnam

Contacts

Primary ContactHa Nguyen Thi Thu, MD.PhD

thuha.ivf@gmail.com0084989661093

Backup ContactLinh Dinh Thuy, MD.PhD

drdinhlinhobgyn@gmail.com

Outcome results